Stifel upgraded Cipher Pharmaceuticals to Buy from Speculative Buy with a price target of C$8, up from C$4.75. The firm has become more comfortable with the steady base business and sees greater potential for capital deployment in 2024, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CPHRF:
